Myeloproliferative Neoplasms

Ruben A. Mesa, Ayalew Tefferi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The therapy of the Philadelphia chromosome (Ph)-negative chronic myeloproliferative neoplasms (MPN), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are at an exciting crossroads. On the one hand, we are experiencing an explosive increase in our understanding of the pathogenetic mechanisms of these disorders and, on the other hand, we are witnessing rapid evolution of targeted therapies hoping to block these pathogenetic mechanisms. The discovery of the JAK2V617F and related mutations in ET, PV, and PMF has ushered a wave of investigation into novel tyrosine kinase inhibitors currently being investigated in clinical trials. Current management of each of these conditions requires a thoughtful consideration of prognosis, and the risks and benefit of each therapeutic modality.

Original languageEnglish (US)
Title of host publicationAdvances in Malignant Hematology
PublisherWiley-Blackwell
Pages47-61
Number of pages15
ISBN (Print)9781405196260
DOIs
StatePublished - Mar 24 2011
Externally publishedYes

Keywords

  • Essential thrombocythemia
  • JAK2
  • Myeloproliferative
  • Polycythemia vera
  • Primary myelofibrosis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Myeloproliferative Neoplasms'. Together they form a unique fingerprint.

Cite this